RadNet (RDNT) Expected to Announce Quarterly Earnings on Monday

RadNet (NASDAQ:RDNT) is anticipated to release its Q1 2025 earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $442.98 million for the quarter. RadNet has set its FY 2025 guidance at EPS.

RadNet (NASDAQ:RDNT) last posted its quarterly earnings data on Thursday, February 27th. The medical research company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.01. The firm had revenue of $477.10 million for the quarter, compared to the consensus estimate of $459.42 million. RadNet had a positive return on equity of 4.29% and a negative net margin of 0.25%. On average, analysts expect RadNet to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

RadNet Stock Down 1.1 %

NASDAQ RDNT opened at $55.77 on Friday. The stock has a market capitalization of $4.18 billion, a P/E ratio of -796.60 and a beta of 1.46. RadNet has a 52 week low of $45.00 and a 52 week high of $93.65. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.16 and a current ratio of 2.16. The stock has a fifty day moving average of $50.77 and a 200-day moving average of $63.38.

Insiders Place Their Bets

In related news, COO Norman R. Hames sold 5,000 shares of the firm’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $50.22, for a total transaction of $251,100.00. Following the sale, the chief operating officer now owns 251,959 shares of the company’s stock, valued at approximately $12,653,380.98. This trade represents a 1.95 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Cornelis Wesdorp sold 1,000 shares of the business’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $50.52, for a total value of $50,520.00. Following the completion of the transaction, the chief executive officer now directly owns 55,995 shares of the company’s stock, valued at approximately $2,828,867.40. The trade was a 1.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,000 shares of company stock worth $1,926,730. Company insiders own 5.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on RDNT. Jefferies Financial Group dropped their price objective on RadNet from $100.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday, January 15th. Barclays cut their price objective on shares of RadNet from $74.00 to $60.00 and set an “overweight” rating on the stock in a report on Monday, March 24th. StockNews.com raised shares of RadNet to a “sell” rating in a report on Wednesday, March 19th. Truist Financial cut their price target on RadNet from $88.00 to $74.00 and set a “buy” rating on the stock in a research note on Friday, April 11th. Finally, Raymond James upgraded RadNet from an “outperform” rating to a “strong-buy” rating and dropped their price objective for the company from $85.00 to $65.00 in a report on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $69.75.

RadNet Company Profile

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.